Torii Pharmaceutical Co (TSE:4551) 3-Year Revenue Growth Rate : 9.40% (As of Mar. 2024)

View and export this data going back to 1993. Start your Free Trial

What is Torii Pharmaceutical Co 3-Year Revenue Growth Rate?

Torii Pharmaceutical Co's Revenue per Share for the three months ended in Mar. 2024 was 円478.60.

During the past 12 months, Torii Pharmaceutical Co's average Revenue per Share Growth Rate was 13.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was 9.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was -0.50% per year. During the past 10 years, the average Revenue per Share Growth Rate was -2.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Torii Pharmaceutical Co was 9.40% per year. The lowest was -13.40% per year. And the median was 3.60% per year.

Competitive Comparison of Torii Pharmaceutical Co's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Torii Pharmaceutical Co's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Torii Pharmaceutical Co's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Torii Pharmaceutical Co's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Torii Pharmaceutical Co's 3-Year Revenue Growth Rate falls into.

Torii Pharmaceutical Co 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Torii Pharmaceutical Co (TSE:4551) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Torii Pharmaceutical Co 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Torii Pharmaceutical Co's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Torii Pharmaceutical Co (TSE:4551) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Torii Pharmaceutical Co Ltd (TSE:4551) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

Torii Nihonbashi Buildingg, 4-1, Nihonbashi-Honcho, 3-chome, Chuo-ku, Tokyo, JPN, 103-8439

Website

http://www.torii.co.jp

Torii Pharmaceutical Co Ltd is a major drug manufacturing company. The company utilizes strategic partnerships with other pharmaceutical companies in order to combine research and marketing functions. Torii's key therapeutic areas include renal diseases, hemodialysis, HIV, skin diseases, and allergens. The vast majority of the company's net mainstay product sales are derived from the renal diseases and hemodialysis operations, followed by HIV. Torii's places its strategic focus on prompt market penetration and expansion of new products as well as maximizing values of mainstay products in each priority area.

Torii Pharmaceutical Co (TSE:4551) Headlines

No Headlines